U.S. markets closed
  • S&P Futures

    3,840.50
    +31.25 (+0.82%)
     
  • Dow Futures

    31,126.00
    +214.00 (+0.69%)
     
  • Nasdaq Futures

    13,045.25
    +134.25 (+1.04%)
     
  • Russell 2000 Futures

    2,232.40
    +33.20 (+1.51%)
     
  • Crude Oil

    62.64
    +1.14 (+1.85%)
     
  • Gold

    1,735.80
    +7.00 (+0.40%)
     
  • Silver

    26.73
    +0.29 (+1.10%)
     
  • EUR/USD

    1.2095
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3982
    +0.0060 (+0.43%)
     
  • USD/JPY

    106.5100
    +0.0080 (+0.01%)
     
  • BTC-USD

    46,357.80
    +238.12 (+0.52%)
     
  • CMC Crypto 200

    926.84
    -6.30 (-0.67%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    29,653.38
    +687.37 (+2.37%)
     

Shattuck Labs Announces Participation in Upcoming March Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
Shattuck Labs, Inc.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

AUSTIN, TX and DURHAM, NC, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Shattuck management will participate in two upcoming investor conferences.

Presentation Details
Conference: Cowen 41st Annual Health Care Conference
Format: Ovarian Cancer Panel discussion
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: March 2, 2021
Time: 12:50 p.m. EST
Webcast Link: The panel discussion will be available live to conference attendees

Conference: Oppenheimer 31st Annual Healthcare Conference
Presenter: Andrew Neill, Shattuck’s Vice President of Finance and Corporate Strategy
Date: March 16, 2021
Time: 11:20 a.m. EST
Webcast Link: Available Here

The live webcast of the Oppenheimer presentation will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.

About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com